Steward Partners Investment Advisory’s Marker Therapeutics MRKR Stock Holding History

Steward Partners Investment Advisory’s Portfolio MRKR Stock Details MRKR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q1	–	Sell	-94	Closed	-$249	–	3383
2022 Q4	$249	Buy	+94	New	+$324	﹤0.01%	3249
2020 Q4	–	Sell	-250	Closed	-$4K	–	2956
2020 Q3	$4K	Hold	250	–	–	﹤0.01%	2437
2020 Q2	$5K	Hold	250	–	–	﹤0.01%	2277
2020 Q1	$4K	Hold	250	–	–	﹤0.01%	2150
2019 Q4	$7K	Hold	250	–	–	﹤0.01%	2151
2019 Q3	$12K	Hold	250	–	–	﹤0.01%	1915
2019 Q2	$19K	Buy	+250	New	+$14.8K	﹤0.01%	1729

Other funds holding MRKR

NMC

NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return

ACM

Aisling Capital Management New York $476M AUM 128.63% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

LFCM

Long Focus Capital Management San Juan, Puerto Rico $3.8B AUM 7.31% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

AAM

AR Asset Management West Hollywood, California $517M AUM 18.31% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

MAA

Matrix Asset Advisors White Plains, New York $1.23B AUM 26.4% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Steward Partners Investment Advisory's MRKR Position: Q1 2023 in Review

Steward Partners Investment Advisory sold out of Marker Therapeutics (MRKR) in Q1 2023, closing a stake of 94 shares — an estimated $249 sold.

Steward Partners Investment Advisory first reported a position in MRKR in Q2 2019 and held it in 7 quarters. The position peaked at $19K in Q2 2019. 30 funds tracked by Wall St. Rank hold MRKR as of Q1 2023.

Steward Partners Investment Advisory reported no remaining Marker Therapeutics position as of Q1 2023 after selling out during the quarter.
Steward Partners Investment Advisory sold 94 Marker Therapeutics shares in Q1 2023, an estimated $249.
Steward Partners Investment Advisory first reported a position in Marker Therapeutics in Q2 2019 and held it in 7 quarters.
Steward Partners Investment Advisory's Marker Therapeutics position peaked at $19K in Q2 2019.
30 funds tracked by Wall St. Rank held Marker Therapeutics as of Q1 2023.

Based on Steward Partners Investment Advisory's 13F filing for Q1 2023, filed 15 May 2023.